Evidence map›Paper›PMID 31799703›Full record

ArticleClinical and experimental immunology2020

The IL-2RG R328X nonsense mutation allows partial STAT-5 phosphorylation and defines a critical region involved in the leaky-SCID phenotype.

A Arcas-García, M Garcia-Prat, M Magallón-Lorenz, A Martín-Nalda, O Drechsel, S Ossowski, L Alonso, J G Rivière, P Soler-Palacín, R Colobran and 3 more

Open access · greenAbstract readCase Reports
In one paragraph

Article in Clinical and experimental immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Identification of novelFrontiers in genetics · 2026
    Article
  3. Article
  4. Article
  5. HemizygousThe application of clinical genetics · 2025
    Article
  6. NovelCentral-European journal of immunology · 2024
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

A Arcas-García *CIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
M Garcia-Prat *Jeffrey Model Foundation Excellence Center, Barcelona, Spain.
M Magallón-LorenzCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
A Martín-NaldaJeffrey Model Foundation Excellence Center, Barcelona, Spain.
O DrechselCenter for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
S OssowskiCenter for Genomic Regulation (CRG), The Barcelona Institute of Science and Technology, Barcelona, Spain.
L AlonsoJeffrey Model Foundation Excellence Center, Barcelona, Spain.
J G RivièreJeffrey Model Foundation Excellence Center, Barcelona, Spain.
P Soler-PalacínJeffrey Model Foundation Excellence Center, Barcelona, Spain.
R ColobranJeffrey Model Foundation Excellence Center, Barcelona, Spain.ORCID 0000-0002-5964-536X
J SayósCIBBIM-Nanomedicine-Immune Regulation and Immunotherapy Group, Institut de Recerca Vall d'Hebron (VHIR), Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
M Martínez-GalloJeffrey Model Foundation Excellence Center, Barcelona, Spain.ORCID 0000-0002-7340-2161
C Franco-JaravaJeffrey Model Foundation Excellence Center, Barcelona, Spain.
Universitat Autònoma de Barcelona · ESCentre for Genomic Regulation · ESVall d'Hebron Hospital Universitari · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In addition to their detection in typical X-linked severe combined immunodeficiency, hypomorphic mutations in the interleukin (IL)-2 receptor common gamma chain gene (IL2RG) have been described in patients with atypical clinical and immunological phenotypes. In this leaky clinical phenotype the diagnosis is often delayed, limiting prompt therapy in these patients. Here, we report the biochemical and functional characterization of a nonsense mutation in exon 8 (p.R328X) of IL2RG in two siblings: a 4-year-old boy with lethal Epstein-Barr virus-related lymphoma and his asymptomatic 8-month-old brother with a T

Indexed as

Codon, NonsenseAnimalsChild, PreschoolChlorocebus aethiopsCOS CellsDNA Mutational AnalysisFemaleHumansInfantInterleukin Receptor Common gamma SubunitMalePhenotypePhosphorylationSiblingsSTAT5 Transcription FactorT-LymphocytesCodon, NonsenseIL2RG protein, humanInterleukin Receptor Common gamma SubunitSTAT5 Transcription Factorhypomorphic mutationsIL-2RGinterleukin receptor common gamma subunitJAK1JAK3leaky SCIDSTAT-5whole exome sequencingX-linked severe combined immunodeficiency

Identifiers

PMID31799703
PMCPMC7066387
OpenAlexW2992380954

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.